Back to results
US 2019/0292275 A1Published application
Sequencing-directed selection of tumor theranostics
AssigneeAffigen, LLC
InventorsDavid J. States, Carlos F. Santos
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins.
Claims2
A humanized construct comprising:
- a. a first domain having an affinity for a clonal lineage specific marker protein (CLSMP);
- and
- b. a second domain having an affinity for an effector antigen selected from the group consisting of CD3, CD28, CTLA4, PD-1, IL-2R, and Fc receptor.
-127. (canceled)
Dependencies are inferred from the claim text.